• IPR-803: Advanced Urokinase Receptor Inhibitor for Tumor Res

  2026-06-03

  IPR-803 empowers cancer researchers with precise, competitive inhibition of the uPAR-uPA axis. Its well-characterized performance in both breast and pancreatic cancer models, including advanced nanomedicine workflows, sets a new benchmark for dissecting metastasis and stroma modulation.

• ECL Chemiluminescent Substrate Detection Kit: Hypersensitive

  2026-06-03

  APExBIO's ECL Chemiluminescent Substrate Detection Kit (Hypersensitive) revolutionizes immunoblotting by enabling detection of proteins at low picogram levels with extended signal duration and low background. Designed for both nitrocellulose and PVDF membranes, it empowers researchers to confidently analyze low-abundance targets, such as those required in advanced translational oncology workflows.

• USP7 Regulates Macrophage Polarization via PKM2 in Acute Pan

  2026-06-02

  This study uncovers how ubiquitin-specific protease 7 (USP7) modulates macrophage polarization and inflammatory responses in severe acute pancreatitis (SAP) through direct regulation of pyruvate kinase M2 (PKM2)-mediated metabolic reprogramming. The findings highlight a novel immunometabolic axis with potential implications for targeted therapies in SAP and related inflammatory conditions.

• Developmental Sequencing of Nurr1+ Neurons in Rat Claustrum

  2026-06-02

  Fang et al. mapped the temporal and spatial birth patterns of Nurr1-positive neurons in the rat claustrum and adjacent lateral cortex, resolving longstanding questions about neurogenetic gradients in this enigmatic region. Their application of 5-ethynyl-2'-deoxyuridine (5-EdU) birth dating coupled with in situ hybridization provides new clarity on the sequential generation of claustral and cortical neuron subtypes, with important implications for neurodevelopmental studies.

• Sodium Picosulfate: Precision Tools for Translational Gut–Br

  2026-06-01

  This article explores the mechanistic underpinnings and translational research opportunities enabled by Sodium Picosulfate, focusing on its role in gastrointestinal motility and the gut–liver–brain axis. Leveraging recent advances in imaging and microbiota-targeted therapies, it provides strategic guidance for researchers seeking to bridge preclinical models and clinical innovation.

• Dabigatran Etexilate: Direct Thrombin Inhibitor for Advanced

  2026-06-01

  Dabigatran etexilate, a potent oral direct thrombin inhibitor, enables researchers to model anticoagulation and stroke prevention with high reproducibility and precise control. Its unique prodrug mechanism and robust in vitro/in vivo profile make it ideal for dissecting the coagulation cascade and improving experimental workflows.

• CDK4/6 and BET Inhibitors Synergize in Suppressing EMT in PD

  2026-05-31

  Gu et al. (2025) demonstrate that combined inhibition of CDK4/6 and BET proteins synergistically suppresses pancreatic tumor growth and reverses epithelial-to-mesenchymal transition (EMT) via modulation of the GSK3β-mediated Wnt/β-catenin pathway. This mechanistic insight highlights a promising therapeutic avenue for overcoming the limited efficacy of current monotherapies in pancreatic ductal adenocarcinoma (PDAC).

• Rapid Purification of Recombinant Annexin V for Biophysical

  2026-05-30

  Burger et al. developed a rapid, efficient method for purifying recombinant Annexin V, addressing the need for high-purity protein in biophysical analyses of its ion channel activity and phosphatidylserine binding. Their protocol leverages reversible calcium-mediated liposome binding and mild cell lysis, minimizing contamination and streamlining downstream applications in apoptosis and cell death research.

• Optimizing hiPSC-Derived Platelet Production via Small Molec

  2026-05-29

  This study presents a cost-effective, optimized protocol for differentiating functional platelets from human induced pluripotent stem cells (hiPSCs), leveraging increased embryoid body (EB) input, human platelet lysate, and small molecule modulators. The approach significantly accelerates differentiation, improves yield, and reduces cost, with implications for scalable platelet manufacture and translational research.

• OPP in B Cell Research: Illuminating Protein Synthesis and I

  2026-05-29

  Discover how O-propargyl-puromycin (OPP) transforms the measurement of protein synthesis in B cells, bridging mitochondrial dynamics and adaptive immunity. This article synthesizes mechanistic breakthroughs on Pcbp1’s role in mitochondrial integrity with strategic protocol guidance, positioning OPP as a powerful, next-generation proteomics reagent. Includes protocol parameters, competitive landscape, translational relevance, and a forward-looking perspective for researchers.

• MOG (35-55): Mechanistic Frontiers and Translational Leverag

  2026-05-28

  This thought-leadership article explores how the MOG (35-55) myelin oligodendrocyte glycoprotein peptide empowers translational researchers to model complex autoimmune neuroinflammation with mechanistic precision. Integrating recent breakthroughs in interferon signaling and PARP7 inhibition, it offers strategic guidance on optimizing experimental autoimmune encephalomyelitis (EAE) models for multiple sclerosis (MS) research, and positions APExBIO's peptide as a catalyst for next-generation discoveries.

• Dantrolene Sodium Salt: Precision Modulation of RyR Pathways

  2026-05-28

  Explore how Dantrolene sodium salt, a potent ryanodine receptor antagonist, uniquely enables advanced control of calcium signaling and DNA repair pathway choice in genome editing and disease models. This analysis goes beyond standard protocols, highlighting mechanistic insights and translational opportunities.

• BMS-777607: c-Met Inhibitor for Enhanced Platelet and Cancer

  2026-05-27

  BMS-777607 enables precise inhibition of MET signaling, streamlining both cancer metastasis and hiPSC-derived platelet production workflows. Discover how recent protocol advances and troubleshooting insights unlock higher assay reproducibility and cost-effectiveness.

• Meta-Analysis Confirms Azilsartan Medoxomil’s Efficacy in Hy

  2026-05-27

  A 2024 systematic review and meta-analysis evaluated azilsartan medoxomil (TAK 491) for hypertension, revealing superior blood pressure reduction versus control therapies and consistent safety, even in diabetic patients. These findings inform both clinical and preclinical research on angiotensin II receptor signaling and essential hypertension treatment.

• Poria cocos Polysaccharides Mitigate ALD via NRF2-Ferroptosi

  2026-05-26

  This study reveals that Poria cocos polysaccharides (PCP) ameliorate alcoholic liver disease (ALD) by modulating the NRF2 signaling pathway and inhibiting ferroptosis. These findings identify a mechanistic link between NRF2 activation, oxidative stress reduction, and liver protection, suggesting new therapeutic angles for ALD intervention.

16363 records 1/1091 page Next 12345 下5页 Last page